Alector LLC, a San Francisco, CA-based biotech company advancing immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, raised $32m in Series C financing.
The round was led by MRL Ventures with participation from OrbiMed, Polaris Partners, Google Ventures, Topspin Partners, Mission Bay Capital and others.
The proceeds will enable Alector to broaden its drug pipeline and to advance its most promising drug candidates towards clinical trials.
Led by Professor Tillman Gerngross, Asa Abeliovich, M.D., Ph.D., and Arnon Rosenthal, Ph.D., Alector combines antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics for Alzheimer’s disease and other forms of dementia and neurodegeneration.
The company has a strategic alliance with Adimab, a technology leader in the discovery of fully human antibodies and bispecifics.